Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers
Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, 6-period crossover study to
evaluate the effects of BPN14770 10 mg and 50 mg in reversing scopolamine-induced cognitive
impairment in healthy volunteers. A positive control, donepezil 10 mg, will be included, and
additivity of BPN14770 50 mg to donepezil 10 mg in reversing scopolamine effects will also be
evaluated.